Remarkably, we discovered that PB CD8+ T cells supplemented with CM from act-A-CD4+ T cell cultures were more competent in killing the targeted primary lung cancer cells, compared to PB CD8+ T cells supplemented with CM from PBS-CD4+ T cell cultures (Fig. 6F, Supplemental Fig. 5C). This evidence concerns the gene CD8A and lung carcinoma.